Chinese pharmaceutical companies are seeing more anti-dumping or anti-subsidy cases. The conflicts are spreading to some major exports.

An increasing number of Chinese pharmaceutical companies, in particular privately-owned firms in coastal areas, are eyeing the international market.

Domestic companies are working to counteract the on-going dumping claims. They understand that they might totally lose the target market if they do not respond.

The E.U.'s proposed plan to impose anti-dumping duty on imported Chinese shoes is unjust and lacks of legitimacy.

This is the first time the growth rate surpassed the country's overall export growth.

Global demand for China's pharmaceuticals is strong.